Melanotan II and its better-known relatives

Melanotan I, Melanotan II and bremelanotide

The names sound like successive editions of the same thing. The development history describes distinct structures: linear Melanotan I, also known as afamelanotide; the shorter, cyclic Melanotan II; and bremelanotide, a further modified descendant. Changing a molecule changes the question being tested.

Melanotan II was designed at the University of Arizona in the late 1980s as a more potent, more stable version of part of alpha-MSH, a natural pigment-stimulating hormone. Its ring-closed structure helps resist breakdown. The approved indications eventually associated with afamelanotide and bremelanotide concern those particular compounds. Melanotan II remains unapproved for every indication.

I enjoy the family history, especially the move from pigmentation research toward sexual function. The similar names, to my mind, have made borrowed reassurance much too easy.

Pigmentation pilot, 1996

The 1996 pigmentation pilot was a Phase I experiment involving 3 healthy male volunteers. Facial, upper-body and buttock pigmentation increased in 2 of 3 without UV exposure. The same study recorded spontaneous erections lasting 1–5 hours, mild nausea and dose-limiting somnolence. Even this tiny experiment contained more than a tanning story.

The pigmentation mechanism begins at MC1R on melanocytes, the cells that make pigment. Receptor activation raises cAMP inside the cell and recruits the PKA–CREB–MITF signalling machinery, increasing tyrosinase activity and favouring darker eumelanin. Melanotan II also activates other melanocortin receptors. Its broad activity explains why appetite and sexual-function research appear alongside skin research in the historical review.

For me, the pilot earns a narrow, interesting entry: a pigmentation effect in a very small group under study conditions. It leaves long-term safety and reliable outcomes in a wider population unresolved.

Erectile function in the crossover study

In the double-blind crossover study of 10 men with psychogenic erectile dysfunction, Melanotan II produced clinically apparent erections in 8 of 10 men. Mean duration of greater than 80% tip rigidity was 38.0 minutes with Melanotan II versus 3.0 minutes with placebo, with p=0.0045. Transient nausea, stretching and yawning required no treatment in that experiment.

That is a striking measured effect. The rigidity figures earn my respect. Their reach is limited by the study’s exact population and small size. A result in men with psychogenic erectile dysfunction cannot stand in for every sexual-function claim made around this peptide, and the tolerability reported in a short trial leaves the later harm reports fully relevant.

Appetite in mice

The nucleus accumbens experiment put Melanotan II directly into a brain region in male mice. The mice ate less and worked less to gain access to food. The researchers found no conditioned taste aversion or change in metabolic rate in that model.

The location and route are unusually important here. This was a targeted animal experiment, with a question about food motivation. Turning it into a human weight-loss claim would discard the very features that made the experiment informative. I prefer its original, more precise subject: how melanocortin signalling in a particular brain region affects eating.

Reported effects, cautions & safety

The renal infarction case report and literature review describe a possible association with loss of blood supply to part of a kidney and discuss earlier reports of severe muscle breakdown and renal failure. The authors consider thrombotic and direct toxic mechanisms. A case report can raise a serious concern without determining how frequently it occurs or proving every step in the causal chain.

The wider published safety record includes changing or newly appearing moles, dysplastic nevi, melanoma reports, priapism and posterior reversible encephalopathy syndrome. A causal link to melanoma has not been established. Priapism is a prolonged, painful erection and a urological emergency; new or changing moles warrant prompt dermatological assessment. Animal work also raises cardiovascular concerns, while long-term human safety remains unknown.

The oral pigmentation case documented brown pigmentation in the gums and cheek lining after Melanotan II use. Cheek pigmentation began fading by 28 days after stopping; gum pigmentation persisted at reduced intensity at 3 months. The different sites followed different courses.

Online accounts describe tanning, patchy fading, reduced appetite, nausea, flushing, libido changes, yawning, fatigue and darker moles. These are anecdotal accounts, not clinical evidence, and cannot supply incidence rates. The social-media analysis examines the distance between promotional framing and documented risk. Product impurities, inaccurate contents and uncertain sterility add further uncertainty to unregulated use.

CLINICAL ACCESS BOUNDARY

Documented risks and clinical oversight

The purity defects and adverse events documented for unregulated Melanotan II remain part of its safety record. At mypromise.com, Promise Peptides prescribes GHK-Cu following a patient-specific decision by its licensed U.S. clinician. Some requests are refused after that assessment. Its care reaches only U.S. patients; both state rules and the requested treatment govern its scope. The compounded GHK-Cu medication has no FDA approval.

Regulatory status

Melanotan II has no approval from the FDA, EMA, TGA, MHRA or any other regulator for any use. No completed Phase II or Phase III trial establishes its efficacy and long-term safety. It is prohibited in sport at all times under WADA’s S0 category for non-approved substances. Prescription access depends on an individual clinical assessment and applicable compounding rules; compounded medication has no FDA approval.

Reassurance requires the correct compound’s clinical record. The comparison with GHK-Cu makes a different separation: a melanocortin agonist studied by injection and a copper-binding peptide with mainly topical human evidence. Sharing a place in skin research gives them very little common clinical ground.